Douglas Barry Biography and Net Worth

Chief Legal Officer of Tango Therapeutics

Doug Barry serves as Chief Legal Officer of Tango. Most recently, Doug served as Vice President of Corporate Law at Alexion Pharmaceuticals, acquired by AstraZeneca PLC in July 2021. During his three years at Alexion, Doug was responsible for public reporting, corporate governance, financing transactions, and litigation. Prior to Alexion, Doug was the Associate General Counsel at Alere Inc., which was acquired by Abbott Laboratories. He has been practicing law for over 20 years.

Doug has a Bachelor of Arts degree in political science from Hobart College, a master’s degree from University of Virginia in international relations, and a juris doctor from Northwestern University School of Law.

What is Douglas Barry's net worth?: The estimated net worth of Douglas Barry is at least $678.84 thousand as of February 4th, 2025. Mr. Barry owns 68,570 shares of Tango Therapeutics stock worth more than $678,843 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Barry may own. Learn More about Douglas Barry's net worth.
How old is Douglas Barry?: Mr. Barry is currently 54 years old. There are 8 older executives and no younger executives at Tango Therapeutics. The oldest executive at Tango Therapeutics is Dr. Barbara L. Weber M.D., President, CEO & Director, who is 67 years old. Learn More on Douglas Barry's age.
How do I contact Douglas Barry?: The corporate mailing address for Mr. Barry and other Tango Therapeutics executives is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. Tango Therapeutics can also be reached via phone at 857-320-4900 and via email at [email protected]. Learn More on Douglas Barry's contact information.
Has Douglas Barry been buying or selling shares of Tango Therapeutics?: Douglas Barry has not been actively trading shares of Tango Therapeutics in the last ninety days. Most recently, Douglas Barry sold 2,774 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a transaction totalling $8,294.26. Following the completion of the sale, the general counsel now directly owns 68,570 shares of the company's stock, valued at $205,024.30. Learn More on Douglas Barry's trading history.
Who are Tango Therapeutics' active insiders?: Tango Therapeutics' insider roster includes Douglas Barry (Chief Legal Officer), Daniella Beckman (CFO), Adam Crystal (President, Research & Development), Mace Rothenberg (Director), and Barbara Weber (CEO). Learn More on Tango Therapeutics' active insiders.
Are insiders buying or selling shares of Tango Therapeutics?: During the last year, insiders at the sold shares 11 times. They sold a total of 3,496,769 shares worth more than $26,422,881.47. The most recent insider tranaction occured on October, 23rd when Major Shareholder Rock Ventures Iv L.P. Third sold 477,401 shares worth more than $4,845,620.15. Insiders at Tango Therapeutics own 7.5% of the company. Learn More about insider trades at Tango Therapeutics.
Information on this page was last updated on 10/23/2025.

Douglas Barry Insider Trading History at Tango Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/4/2025	Sell	2,774	$2.99	$8,294.26	68,570
2/7/2024	Sell	1,354	$12.62	$17,087.48	43,981

Douglas Barry Buying and Selling Activity at Tango Therapeutics

Tango Therapeutics Company Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $9.90

$9.46

$10.22

50 Day Range

MA: $8.54

$6.91

$10.92

2 Week Range

Now: $9.90

$1.03

$11.20

Volume

2,780,322 shs

Average Volume

2,935,051 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Douglas Barry Biography and Net Worth

What is Douglas Barry's net worth?

How old is Douglas Barry?

How do I contact Douglas Barry?

Has Douglas Barry been buying or selling shares of Tango Therapeutics?

Who are Tango Therapeutics' active insiders?

Are insiders buying or selling shares of Tango Therapeutics?